^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

MUC16 elevation

i
Other names: MUC16, Mucin 16, Cell Surface Associated, Ovarian Cancer-Related Tumor Marker CA125, Ovarian Carcinoma Antigen CA125, Mucin-16, CA125, CA125 Ovarian Cancer Antigen, Mucin-16 Short Isoform, Mucin-16 Long Isoform, CA-125, MUC-16
Entrez ID:
Related biomarkers:
Phase 3
ImmunoGen, Inc.
Recruiting
Last update posted :
06/13/2024
Initiation :
12/27/2022
Primary completion :
03/01/2027
Completion :
04/01/2029
FOLR1 • BRCA • MUC16
|
FOLR1 expression • MUC16 elevation
|
Avastin (bevacizumab) • Elahere (mirvetuximab soravtansine-gynx)
Phase 2
M.D. Anderson Cancer Center
Recruiting
Last update posted :
05/30/2024
Initiation :
12/12/2023
Primary completion :
09/30/2025
Completion :
09/30/2027
BRCA1 • BRCA2 • MUC16
|
MUC16 elevation
|
Keytruda (pembrolizumab) • Avastin (bevacizumab) • cyclophosphamide
Phase N/A
Alliance for Clinical Trials in Oncology
Recruiting
Last update posted :
05/23/2024
Initiation :
08/01/2022
Primary completion :
01/31/2025
Completion :
02/01/2025
MUC16
|
MUC16 elevation
Phase N/A
Mayo Clinic
Recruiting
Last update posted :
05/16/2024
Initiation :
08/03/2021
Primary completion :
06/30/2025
Completion :
12/30/2025
MUC16
|
MUC16 elevation
Phase N/A
AGO Study Group
Active, not recruiting
Last update posted :
05/09/2024
Initiation :
07/01/2016
Primary completion :
12/01/2024
Completion :
02/01/2025
MUC16
|
MUC16 elevation
Phase 1/2
Sham Sunder Kakar
Recruiting
Last update posted :
04/24/2024
Initiation :
05/01/2024
Primary completion :
11/01/2026
Completion :
11/01/2027
MUC16
|
MUC16 elevation
|
pegylated liposomal doxorubicin
Phase 1/2
National Cancer Institute (NCI)
Active, not recruiting
Last update posted :
04/08/2024
Initiation :
04/14/2010
Primary completion :
10/31/2018
Completion :
02/13/2025
BRCA • MUC16
|
BRCA mutation • MUC16 elevation
|
Lynparza (olaparib) • Recentin (cediranib)
Phase 1
Mayo Clinic
Completed
Last update posted :
01/15/2024
Initiation :
04/19/2004
Primary completion :
08/01/2012
Completion :
11/07/2017
MUC16 • CD4
|
MUC16 elevation
Phase 1
Ludwig Institute for Cancer Research
Completed
Last update posted :
10/04/2023
Initiation :
11/14/2008
Primary completion :
01/24/2011
Completion :
01/24/2011
MUC16 • CTAG1B • CTAG2
|
MUC16 elevation
|
Leukine (sargramostim)
Phase 1
Mayo Clinic
Active, not recruiting
Last update posted :
10/02/2023
Initiation :
02/24/2014
Primary completion :
06/30/2024
Completion :
06/30/2025
MUC16
|
MUC16 elevation
|
Avastin (bevacizumab) • cisplatin • albumin-bound paclitaxel • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Zirabev (bevacizumab-bvzr) • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • Vasforda (bevacizumab biosimilar)
Phase 2
University of Chicago
Suspended
Last update posted :
08/28/2023
Initiation :
02/25/2015
Primary completion :
02/25/2025
Completion :
02/25/2025
CEACAM5 • MUC16
|
MUC16 elevation
|
metformin
Phase 2
InxMed (Shanghai) Co., Ltd.
Recruiting
Last update posted :
08/28/2023
Initiation :
09/06/2022
Primary completion :
12/01/2024
Completion :
12/01/2025
MUC16
|
MUC16 elevation
|
pegylated liposomal doxorubicin • ifebemtinib (IN10018)
Phase 3
Swiss GO Trial Group
Recruiting
Last update posted :
06/27/2023
Initiation :
11/05/2020
Primary completion :
10/01/2025
Completion :
10/01/2030
ER • MUC16
|
MUC16 elevation
|
letrozole
Phase 1
Cancer Research UK
Completed
Last update posted :
06/05/2023
Initiation :
02/16/2016
Primary completion :
06/22/2021
Completion :
07/30/2021
MUC16
|
MUC16 elevation
|
MOv18 IgE
Phase 1b
Genelux Corporation
Completed
Last update posted :
01/05/2023
Initiation :
05/01/2016
Primary completion :
12/31/2021
Completion :
12/31/2022
MUC16
|
MUC16 elevation
|
Avastin (bevacizumab) • olvimulogene nanivacirepvec (GL-ONC1)
Phase 3
University College, London
Recruiting
Last update posted :
09/27/2022
Initiation :
06/15/2018
Primary completion :
12/01/2023
Completion :
12/01/2023
BRCA • MUC16
|
BRCA mutation • MUC16 elevation
|
Lynparza (olaparib) • Recentin (cediranib)
Phase 1
Ronald Buckanovich
Completed
Last update posted :
09/07/2022
Initiation :
06/10/2017
Primary completion :
06/01/2020
Completion :
08/01/2022
MUC16
|
MUC16 elevation
|
carboplatin • paclitaxel • Kisqali (ribociclib)
Phase 4
Women's Hospital School Of Medicine Zhejiang Un...
Active, not recruiting
Last update posted :
07/18/2022
Initiation :
03/19/2019
Primary completion :
03/31/2024
Completion :
03/31/2024
MUC16
|
MUC16 elevation
|
carboplatin • paclitaxel • pegylated liposomal doxorubicin • Duomeisu (pegylated liposomal doxorubicin) • doxorubicin liposomal
Phase N/A
Assistance Publique - Hôpitaux de Paris
Active, not recruiting
Last update posted :
06/30/2022
Initiation :
05/23/2019
Primary completion :
05/01/2023
Completion :
05/01/2027
MUC16 • MIR200B
|
MUC16 elevation
Phase 1
Tyrogenex
Completed
Last update posted :
02/28/2022
Initiation :
02/01/2011
Primary completion :
01/01/2014
Completion :
01/01/2017
MUC16
|
MUC16 elevation
|
Fumena (vorolanib)
Phase 2
Fudan University
Recruiting
Last update posted :
02/03/2022
Initiation :
07/02/2021
Primary completion :
07/02/2023
Completion :
07/02/2023
MUC16
|
MUC16 elevation
|
cisplatin • gemcitabine • albumin-bound paclitaxel
Phase 1/2
Xing Xie
Recruiting
Last update posted :
01/25/2022
Initiation :
07/01/2020
Primary completion :
01/01/2024
Completion :
01/01/2025
BRCA1 • BRCA2 • MUC16
|
BRCA2 mutation • BRCA1 mutation • MUC16 elevation
|
Lynparza (olaparib) • AiRuiYi (fluzoparib) • arsenic trioxide
Phase N/A
Assistance Publique - Hôpitaux de Paris
Withdrawn
Last update posted :
12/10/2021
Initiation :
06/22/2021
Primary completion :
06/22/2021
Completion :
06/22/2021
BRCA • MUC16
|
MUC16 elevation
Phase 2
Peking Union Medical College Hospital
Recruiting
Last update posted :
09/01/2021
Initiation :
05/21/2020
Primary completion :
03/01/2022
Completion :
06/01/2022
MUC16
|
MUC16 elevation
|
Zejula (niraparib) • etoposide oral
Phase 1/2
Leiden University Medical Center
Recruiting
Last update posted :
04/01/2021
Initiation :
08/01/2018
Primary completion :
08/01/2021
Completion :
12/01/2021
MUC16
|
MUC16 elevation
|
carboplatin • paclitaxel
Phase 3
Novartis Pharmaceuticals
Completed
Last update posted :
02/16/2021
Initiation :
05/26/2009
Primary completion :
07/08/2012
Completion :
08/24/2017
MUC16
|
MUC16 elevation
|
pazopanib
Phase 2
Xiaoxiang Chen
Recruiting
Last update posted :
11/10/2020
Initiation :
11/06/2020
Primary completion :
03/01/2022
Completion :
10/01/2022
HRD • MUC16
|
HRD • MUC16 elevation
|
Avastin (bevacizumab) • Zejula (niraparib)
Phase 2
Mayo Clinic
Completed
Last update posted :
10/23/2020
Initiation :
11/14/2014
Primary completion :
06/15/2016
Completion :
06/21/2018
ER • MUC16
|
ER positive • MUC16 elevation
|
everolimus • letrozole
Phase 1/2
Astellas Pharma Inc
Completed
Last update posted :
11/19/2019
Initiation :
08/05/2009
Primary completion :
08/01/2014
Completion :
08/25/2014
MUC16
|
MUC16 elevation
|
paclitaxel • linsitinib (ASP7487)
Phase 1
Mayo Clinic
Completed
Last update posted :
08/02/2019
Initiation :
11/02/2012
Primary completion :
01/10/2014
Completion :
04/06/2015
MUC16
|
MUC16 elevation
Phase 2
National Cancer Institute (NCI)
Completed
Last update posted :
07/23/2019
Initiation :
12/01/2009
Primary completion :
07/01/2012
Completion :
07/29/2012
MUC16
|
MUC16 elevation
|
cisplatin • carboplatin • Beleodaq (belinostat)
Phase N/A
M.D. Anderson Cancer Center
Unknown status
Last update posted :
06/24/2019
Initiation :
02/12/2002
Primary completion :
02/01/2020
Completion :
02/01/2021
MUC16
|
MUC16 elevation
Phase 1
Gynecologic Oncology Group
Completed
Last update posted :
03/12/2019
Initiation :
07/09/2012
Primary completion :
12/30/2014
Completion :
01/27/2018
MUC16
|
MUC16 elevation
|
cisplatin • pegylated liposomal doxorubicin • Myocet (non-pegylated liposomal doxorubicin) • Duomeisu (pegylated liposomal doxorubicin) • doxorubicin liposomal
Phase 2
National Cancer Institute (NCI)
Completed
Last update posted :
08/29/2018
Initiation :
04/01/2006
Primary completion :
06/01/2010
Completion :
01/15/2018
MUC16
|
MUC16 elevation
|
Recentin (cediranib)
Phase N/A
Memorial Sloan Kettering Cancer Center
Completed
Last update posted :
06/12/2018
Initiation :
10/01/2010
Primary completion :
09/01/2017
Completion :
09/01/2017
ALK • MUC16
|
MUC16 elevation
|
Avastin (bevacizumab) • polyvalent vaccine-KLH conjugate